Analysis of Cell Therapy Market Size by Research Nester Reveals the Market to Grow with a CAGR of ~21% During 2024-2036 and Attain ~USD 47.9 Billion by 2036

Research Nester assesses the growth and market size of the global cell therapy market which is anticipated to be on account of the growing importance of automation in the medical sector and the growing burden of chronic diseases across the globe.

Research Nester’s recent market research analysis on “Cell Therapy Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global cell therapy market in terms of market segmentation by therapy type, therapeutic area, end-user, technology, use, and by region.

Growing Prevalence of Genetic Disorders to Promote Global Market Share of Cell Therapy

The global cell therapy market is estimated to grow majorly on account of the increasing burden of genetic illness. People from all over the world are affected by genetic disorders for the duration of their lives due to the high birth rate, large population, and widespread preference for consanguineous marriage.

As per the World Health Organization (WHO), in developed nations, genetic illnesses and congenital abnormalities cause over 50% of childhood fatalities, account for up to 30% of pediatric hospital admissions, and affect 2%–5% of live births.

Gene and stem cell therapies exhibit significant potential in the management of numerous hereditary illnesses, therefore numerous gene therapy products have received approval from the US Food and Drug Administration for use in treating these diseases.

Some of the major growth factors and challenges that are associated with the growth of the global cell therapy market are:

Growth Drivers:

• Surge in Research and Development Globally
• Rising Senior Population

Challenges:

The exorbitant cost of cell therapy and the lack of awareness are some of the major factors anticipated to hamper the global market size of cell therapy. Due to the high costs of administration and manufacturing, CAR T-cell therapy is now among the most expensive treatment options. As a result, people living in developing regions are unable to afford such treatments and also have limited access to the resources available.

Access our detailed report at: https://www.researchnester.com/reports/cell-therapy-market/6155

By therapy type, the global cell therapy market is segmented into allogeneic, and autologous. The autologous segment is to garner the highest revenue by the end of 2036 by growing at a significant CAGR over the forecast period. To cure cancer, autologous cell therapy usually starts with removing tissues or cells from the patient's body, which are then activated and expanded ex vivo before being reintroduced.

Autologous cell therapies represent a significant breakthrough in personalized medicine, representing an innovative treatment approach that has demonstrated remarkable efficacy in treating grave and potentially fatal illnesses.

Besides this, allogeneic, also known as universal, cell therapies treat one or more patients using cells or tissues from a single source, and are considered a successful therapeutic choice for both malignant and non-malignant disorders.

The oncology section is anticipated to increase at the fastest rate over the forecast period.

CAR-T cell therapy is one of the most promising treatments for blood cancer since it stimulates the immune system to target and destroy cancer cells.

By region, the North American cell therapy market is to generate the highest revenue by the end of 2036. This growth is anticipated by higher investment in the medical sector. As a result, more and more patients with lesser incomes can pay for more gene and cell therapies in the area.

Also, growing developments in medical research have been made by the American healthcare system, which is expected to lead to ongoing advancements in cell therapy technologies in the area.

Furthermore, the cell therapy market in Europe is likely to witness lucrative growth in the coming years led by the ongoing clinical trials. For instance, more than 140 cell therapy clinical trials, including around 26 phase 3 trials, have been carried out in the EU so far.

Moreover, in recent years, hospitals all around Europe which are known for their innovative supply chain, manufacturing, and marketing techniques have been manufacturing their cell therapies.

In addition, there is a growing burden of cancer in Europe which may drive the demand for cell therapy.

As per the World Health Organization (WHO), in Europe, cancer is the second leading cause of death and morbidity, accounting for almost 3.7 million new cases and 1.9 million deaths annually.

This report also provides the existing competitive scenario of some of the key players of the global cell therapy market which includes company profiling of Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JCR Pharmaceuticals Co., Ltd., JW Therapeutics, Atara Biotherapeutics     

Request Report Sample@ https://www.researchnester.com/sample-request-6155

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919